https://www.selleckchem.com/pr....oducts/amg-perk-44.h
Since the discovery of CHD1L in 2008 it has emerged as an oncogene implicated in the pathology and poor prognosis of a variety of cancers, including gastrointestinal cancers. However, a mechanistic understanding of CHD1L as a driver of colorectal cancer (CRC) has been limited. Until now, there have been no reported inhibitors of CHD1L, also limiting its development as a molecular target. We sought to characterize the clinicopathological link between CHD1L and CRC, determine the mechanism(s) by which CHD1L drives malignant CRC, and d
Like
Comment
Share
